Performance Forecast - The company expects a net loss in the current reporting period, with estimated losses ranging from 90 million to 120 million yuan, compared to a loss of 86.58 million yuan in the same period last year [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be a loss between 100 million and 130 million yuan, compared to a loss of 131.47 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss between 0.0952 yuan and 0.1269 yuan, compared to a loss of 0.0916 yuan in the same period last year [1] Reasons for Performance Changes - The overall performance did not meet expectations due to several factors, despite some business segments showing positive development, such as the new materials business [1] - The expansion of the sub-therapeutic equipment market and core technology research, along with continuous investment in new isotope preparation technology, led to an increase in losses in that business segment [1] - The optical multiplier business has not yet achieved profitability due to increased R&D investment aimed at improving production line yield [1] - A decrease in the number of accelerator deliveries compared to the previous year resulted in temporary losses for that segment [1] - A reduction in government subsidies recognized in the current period also contributed to the overall losses [1]